Vident Investment Advisory, LLC Zynerba Pharmaceuticals, Inc. Transaction History

Vident Investment Advisory, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.87 - $1.36 $12,160 - $19,010	13,978 Added 15.29%	105,398 $77,000
Q2 2022 Aug 15, 2022	BUY	$0.86 - $2.06 $6,400 - $15,332	7,443 Added 8.86%	91,420 $104,000
Q1 2022 May 16, 2022	BUY	$1.83 - $3.02 $61,154 - $100,922	33,418 Added 66.1%	83,977 $172,000
Q4 2021 Feb 14, 2022	BUY	$2.88 - $4.3 $5,639 - $8,419	1,958 Added 4.03%	50,559 $146,000
Q3 2021 Nov 12, 2021	BUY	$3.72 - $5.35 $180,795 - $260,015	48,601 New	48,601 $206,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.